Benjamin Hickey

Insider Reports History

Entity
Individual
Location
C/O Mirati Therapeutics, 9393 Towne Centre Drive Suite 200, San Diego, CA
Signature
/s/ Maiken Keson-Brookes, attorney-in-fact for Benjamin Hickey
All insider transactions
Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date

Holdings reported by Benjamin Hickey:

Stock Role Class Num Shares Value Price $ Report Date Ownership
BRISTOL MYERS SQUIBB CO President, RayzeBio Org. Restricted Stock Units 9.86K $480K $48.67 Mar 1, 2024 Direct
BRISTOL MYERS SQUIBB CO President, RayzeBio Org. Market Share Units 3.87K $208K $53.79 Mar 10, 2024 Direct
BRISTOL MYERS SQUIBB CO President, RayzeBio Org. Common Stock, $0.10 par value 780 $42K $53.79 Mar 10, 2024 Direct
Mural Oncology plc Director Stock Option (right to buy) 8.46K $28.3K $3.35 May 30, 2024 Direct
BRISTOL MYERS SQUIBB CO President, RayzeBio Org. Common Stock, $0.10 par value 91 $4.89K $53.79 Mar 10, 2024 By Spouse
Surface Oncology, Inc. Director Stock Option (Right to Buy) 24K Jun 8, 2022 Direct
BRISTOL MYERS SQUIBB CO President, RayzeBio Org. Performance Shares 5.81K Mar 10, 2024 Direct
Mirati Therapeutics, Inc. EVP, Chief Commercial Officer Common Stock 0 $59.02 Jan 23, 2024 Direct
Mirati Therapeutics, Inc. EVP, Chief Commercial Officer Option to Purchase Common Stock 0 Jan 23, 2024 Direct

Insider Reports Filed by Benjamin Hickey

Symbol Company Period Transactions Value $ Form Type Date Filed Role
MURA Mural Oncology plc May 30, 2024 1 $0 4/A Jun 5, 2024 Director
MURA Mural Oncology plc May 30, 2024 1 $28.3K 4 Jun 3, 2024 Director
BMY BRISTOL MYERS SQUIBB CO Mar 10, 2024 2 $0 4 Mar 12, 2024 President, RayzeBio Org.
BMY BRISTOL MYERS SQUIBB CO Mar 1, 2024 1 $0 4 Mar 4, 2024 President, RayzeBio Org.
BMY BRISTOL MYERS SQUIBB CO Feb 26, 2024 0 $0 3 Mar 4, 2024 President, RayzeBio Org.
MRTX Mirati Therapeutics, Inc. Jan 23, 2024 5 $0 4 Jan 23, 2024 EVP, Chief Commercial Officer
MRTX Mirati Therapeutics, Inc. Jan 16, 2024 2 -$94.3K 4 Jan 18, 2024 EVP, Chief Commercial Officer
MRTX Mirati Therapeutics, Inc. Jan 8, 2024 1 -$123K 4 Jan 9, 2024 EVP, Chief Commercial Officer
MRTX Mirati Therapeutics, Inc. Dec 29, 2023 1 $1M 4 Jan 3, 2024 EVP, Chief Commercial Officer
MURA Mural Oncology plc Dec 14, 2023 1 $0 4 Dec 18, 2023 Director
MRTX Mirati Therapeutics, Inc. Dec 13, 2023 1 -$126K 4 Dec 14, 2023 EVP, Chief Commercial Officer
MURA Mural Oncology plc Oct 31, 2023 0 $0 3 Nov 7, 2023 Director
MRTX Mirati Therapeutics, Inc. Aug 9, 2023 1 $825K 4 Aug 10, 2023 EVP, Chief Commercial Officer
MRTX Mirati Therapeutics, Inc. Jan 20, 2023 2 $0 4 Jan 24, 2023 EVP, Chief Commercial Officer
MRTX Mirati Therapeutics, Inc. Jan 17, 2023 2 -$66.4K 4 Jan 19, 2023 EVP, Chief Commercial Officer
MRTX Mirati Therapeutics, Inc. Jan 9, 2023 1 -$94.7K 4 Jan 10, 2023 EVP, Chief Commercial Officer
MRTX Mirati Therapeutics, Inc. Dec 19, 2022 2 -$131K 4 Dec 21, 2022 EVP, Chief Commercial Officer
SURF Surface Oncology, Inc. Jun 8, 2022 1 $0 4 Jun 10, 2022 Director
MRTX Mirati Therapeutics, Inc. Jan 14, 2022 3 -$75.5K 4 Jan 18, 2022 EVP, Chief Commercial Officer
MRTX Mirati Therapeutics, Inc. Jan 7, 2022 1 -$267K 4 Jan 7, 2022 EVP, Chief Commercial Officer
SURF Surface Oncology, Inc. Jan 3, 2022 1 $0 4 Jan 5, 2022 Director
SURF Surface Oncology, Inc. Dec 9, 2021 0 $0 3 Dec 16, 2021 Director